Glycostem is at the forefront of cellular immunotherapy, focusing on the development of stem cell-derived Natural Killer (NK) cells to combat various cancers, including acute myeloid leukemia (AML) and multiple myeloma (MM). Their lead product, oNKord®, is an off-the-shelf NK cell therapy derived from umbilical cord blood (UCB) CD34+ stem cells. This innovative approach offers several advantages, such as immediate availability, safety without the risk of Cytokine Release Syndrome (CRS), and cost-effectiveness. Glycostem's pipeline also includes the development of CAR-engineered NK cell therapies and T-cell receptor expression NK cell products, aiming to address significant unmet medical needs in cancer treatment.

The company employs a proprietary, GMP-compliant platform technology that facilitates the closed-system culture of CD34+ hematopoietic stem and progenitor cells, allowing for the efficient production of high-quality NK cells devoid of T-cell contamination. This technology utilizes closed bioreactor systems and a specialized, feeder cell-free culture medium, enabling the generation of safe and cost-effective NK cell products. Glycostem's commitment to advancing NK cell therapies is underscored by ongoing clinical trials, including a pivotal phase I/IIa trial for oNKord® in AML patients, which aims to establish the safety and efficacy of this promising treatment.

Netherlands

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

Glycostem

Company Details